Bayer is set to acquire the precision therapeutics developer backed by Alexandria Venture Investments, Celgene and SoftBank, with another $500m in milestone payments up for grabs.
Pharmaceutical firm Bayer agreed today to pay $1.5bn upfront to acquire Vividion Therapeutics, a US-based, corporate-backed precision medicine developer.
Vividion stands to gain up to an additional $500m in milestone payments. The transaction is expected to close in the third quarter of this year.
Founded in 2017, Vividion is developing precision small-molecule therapies targeting cancer and immune system disorders. Its lead programmes include treatments for NRF2 mutant cancers and inflammatory diseases such as irritable bowel syndrome.
Vividion will continue to…
